Skip to main content

Advertisement

SpringerLink
Log in

Cuproptosis Regulates Microenvironment and Affects Prognosis in Prostate Cancer

  • Research
  • Published:
Biological Trace Element Research Aims and scope Submit manuscript

Abstract

Current immunotherapy for prostate cancer is still in the stage of clinical trials. This delay is thought to be caused by an unclear regulatory mechanism of the immune microenvironment, which makes it impossible to distinguish patients suitable for immunotherapy. Cuprotosis may be related to the heterogeneity of immune microenvironment, which was regarded as a new copper-dependent cell death mode, was proposed, and gain attention. We explored for the first time the relationship between cuprotosis and the immune microenvironment of prostate cancer and constructed cuprotosis score. RNA sequencing data sets for prostate cancer were downloaded from public databases. Consensus clustering was applied to distinguish cuprotosis phenotype based on the expression of cuproptosis-related genes (CRGs) identified as prognostic factors. Genomic phenotypes of CRG clusters were depicted via consensus clustering. Cuprotosis score was established on the basis of differentially expressed genes (DEGs) identified as prognostic factors via principal component analysis. Cuprotosis score = the first principal component of prognostic factors + the second principal component of prognostic factors. The value of cuproptosis score in predicting prognosis and immunotherapy response was evaluated. PDHA1 (HR = 3.86, P < 0.001) and GLS (HR = 1.75, P = 0.018) were risk factors for prognosis of prostate cancer patients, while DBT (HR = 0.66, P = 0.048) was a favorable factor for prognosis of prostate cancer patients. CRG clusters had different prognosis and immune cell infiltration. So as gene clusters. Prostate cancer patients with low cuprotosis score showed better prognosis for biochemical relapse-free survival. Cuprotosis score is accompanied with high immune score and Gleason score. As cuprotosis genes, PDHA1, GLS, and DBT were identified as independent prognostic factors of prostate cancer. Cuprotosis score was established via principal component analysis of PDHA1, GLS, and DBT, which can be used as a predictor of prognosis and immunotherapy response of prostate cancer patients, and can characterize immune cells infiltration in tumors. Cuproptosis was involved in the regulation of immune microenvironment, which may depend on the effect of tricarboxylic acid cycle. Our study provided clues to reveal the relationship between copper death and immune microenvironment, highlighted the clinical significance of cuproptosis, and provided a reference for the development of personalized immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability

The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Rebello RJ, Oing C, Knudsen KE et al (2021) Prostate cancer[J]. Nat Rev Dis Primers 7(1):9

    Article  PubMed  Google Scholar 

  2. Sandhu S, Moore CM, Chiong E et al (2021) Prostate cancer[J]. Lancet 398(10305):1075–1090

    Article  CAS  PubMed  Google Scholar 

  3. Achard V, Putora PM, Omlin A et al (2022) Metastatic prostate cancer: treatment options[J]. Oncology 100(1):48–59

    Article  CAS  PubMed  Google Scholar 

  4. Lowrance WT, Breau RH, Chou R et al (2021) Advanced prostate cancer: AUA/ASTRO/SUO guideline part I[J]. J Urol 205(1):14–21

    Article  PubMed  Google Scholar 

  5. Teo MY, Rathkopf DE, Kantoff P (2019) Treatment of advanced prostate cancer[J]. Annu Rev Med 70:479–499

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Komura K, Sweeney CJ, Inamoto T et al (2018) Current treatment strategies for advanced prostate cancer[J]. Int J Urol 25(3):220–231

    Article  PubMed  Google Scholar 

  7. Cha HR, Lee JH, Ponnazhagan S (2020) Revisiting immunotherapy: a focus on prostate cancer[J]. Cancer Res 80(8):1615–1623

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Isaacsson VP, Antonarakis ES (2018) PD-1/PD-L1 pathway inhibitors in advanced prostate cancer[J]. Expert Rev Clin Pharmacol 11(5):475–486

    Article  Google Scholar 

  9. Abbott M, Ustoyev Y (2019) Cancer and the immune system: the history and background of immunotherapy[J]. Semin Oncol Nurs 35(5):150923

    Article  PubMed  Google Scholar 

  10. Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications[J]. Cell Mol Immunol 17(8):807–821

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Hong WX, Haebe S, Lee AS et al (2020) Intratumoral immunotherapy for early-stage solid tumors[J]. Clin Cancer Res 26(13):3091–3099

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Chakravarty D, Huang L, Kahn M et al (2020) Immunotherapy for metastatic prostate cancer: current and emerging treatment options[J]. Urol Clin North Am 47(4):487–510

    Article  PubMed  Google Scholar 

  13. O’Donnell JS, Teng M, Smyth MJ (2019) Cancer immunoediting and resistance to T cell-based immunotherapy[J]. Nat Rev Clin Oncol 16(3):151–167

    Article  PubMed  Google Scholar 

  14. Tsaur I, Brandt MP, Juengel E et al (2021) Immunotherapy in prostate cancer: new horizon of hurdles and hopes[J]. World J Urol 39(5):1387–1403

    Article  PubMed  Google Scholar 

  15. Mitsogiannis I, Tzelves L, Dellis A et al (2022) Prostate cancer immunotherapy[J]. Expert Opin Biol Ther 22(5):577–590

    Article  CAS  PubMed  Google Scholar 

  16. Lei X, Lei Y, Li JK et al (2020) Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy[J]. Cancer Lett 470:126–133

    Article  CAS  PubMed  Google Scholar 

  17. Xiao J, Liu Z, Wang J et al (2022) Identification of cuprotosis-mediated subtypes, the development of a prognosis model, and influence immune microenvironment in hepatocellular carcinoma[J]. Front Oncol 12:941211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Xu Y, Li H, Lan A et al (2022) Cuprotosis-related genes: predicting prognosis and immunotherapy sensitivity in pancreatic cancer patients[J]. J Oncol 2022:2363043

    Article  PubMed  PubMed Central  Google Scholar 

  19. Li Z, Zhang H, Wang X et al (2022) Identification of cuproptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer[J]. Front Immunol 13:996836

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Guo H, Wang Y, Cui H et al (2022) Copper induces spleen damage through modulation of oxidative stress, apoptosis, DNA damage, and inflammation[J]. Biol Trace Elem Res 200(2):669–677

    Article  CAS  PubMed  Google Scholar 

  21. Chen Y (2022) Identification and validation of cuproptosis-related prognostic signature and associated regulatory axis in uterine corpus endometrial carcinoma[J]. Front Genet 13:912037

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Yuan H, Qin X, Wang J et al (2022) The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma[J]. Front Immunol 13:971142

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Liu J, Lu Y, Dai Y et al (2022) A comprehensive analysis and validation of cuproptosis-associated genes across cancers: overall survival, the tumor microenvironment, stemness scores, and drug sensitivity[J]. Front Genet 13:939956

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Theophanides T, Anastassopoulou J (2002) Copper and carcinogenesis[J]. Crit Rev Oncol Hematol 42(1):57–64

    Article  CAS  PubMed  Google Scholar 

  25. Gaetke LM, Chow-Johnson HS, Chow CK (2014) Copper: toxicological relevance and mechanisms[J]. Arch Toxicol 88(11):1929–1938

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Kahlson MA, Dixon SJ (2022) Copper-induced cell death[J]. Science 375(6586):1231–1232

    Article  CAS  PubMed  Google Scholar 

  27. Cobine PA, Brady DC (2022) Cuproptosis: cellular and molecular mechanisms underlying copper-induced cell death[J]. Mol Cell 82(10):1786–1787

    Article  CAS  PubMed  Google Scholar 

  28. Jiang Y, Huo Z, Qi X et al (2022) Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes[J]. Nanomedicine (Lond) 17(5):303–324

    Article  CAS  PubMed  Google Scholar 

  29. Krishnamoorthy L, Cotruvo JJ, Chan J et al (2016) Copper regulates cyclic-AMP-dependent lipolysis[J]. Nat Chem Biol 12(8):586–592

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Collins CJ, Yi F, Dayuha R et al (2021) Direct measurement of ATP7B peptides is highly effective in the diagnosis of Wilson disease[J]. Gastroenterology 160(7):2367–2382

    Article  CAS  PubMed  Google Scholar 

  31. Squitti R, Ventriglia M, Simonelli I et al (2021) Copper imbalance in Alzheimer’s disease: meta-analysis of serum, plasma, and brain specimens, and replication study evaluating ATP7B gene variants. Biomolecules 11(7)

  32. DiNicolantonio JJ, Mangan D, O’Keefe JH (2018) Copper deficiency may be a leading cause of ischaemic heart disease[J]. Open Heart 5(2):e784

    Article  Google Scholar 

  33. Schepisi G, Cursano MC, Casadei C et al (2019) CAR-T cell therapy: a potential new strategy against prostate cancer[J]. J Immunother Cancer 7(1):258

    Article  PubMed  PubMed Central  Google Scholar 

  34. Sena LA, Denmeade SR, Antonarakis ES (2021) Targeting the spectrum of immune checkpoints in prostate cancer[J]. Expert Rev Clin Pharmacol 14(10):1253–1266

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Bian Z, Fan R, Xie L (2022) A novel cuproptosis-related prognostic gene signature and validation of differential expression in clear cell renal cell carcinoma. Genes (Basel) 13(5)

  36. Davis CI, Gu X, Kiefer RM et al (2020) Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation[J]. Metallomics 12(12):1995–2008

    Article  CAS  PubMed  Google Scholar 

  37. Scagliola A, Mainini F, Cardaci S (2020) The tricarboxylic acid cycle at the crossroad between cancer and immunity[J]. Antioxid Redox Signal 32(12):834–852

    Article  CAS  PubMed  Google Scholar 

  38. Vander HM, DeBerardinis RJ (2017) Understanding the intersections between metabolism and cancer biology[J]. Cell 168(4):657–669

    Article  Google Scholar 

  39. Jiang P, Gu S, Pan D et al (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response[J]. Nat Med 24(10):1550–1558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Cheng X, Zeng Z, Yang H et al (2023) Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma[J]. BMC Cancer 23(1):105

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Jiang S, Li Z, Dou R et al (2022) Construction and validation of a novel cuproptosis-related long noncoding RNA signature for predicting the outcome of prostate cancer[J]. Front Genet 13:976850

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Jin L, Mei W, Liu X et al (2022) Identification of cuproptosis-related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer[J]. Front Immunol 13:974034

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Lv H, Liu X, Zeng X et al (2022) Comprehensive analysis of cuproptosis-related genes in immune infiltration and prognosis in melanoma[J]. Front Pharmacol 13:930041

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Zhang Z, Zeng X, Wu Y et al (2022) Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in hepatocellular carcinoma[J]. Front Immunol 13:925618

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Wang W, Lu Z, Wang M et al (2022) The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma[J]. Front Immunol 13:998236

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by Hebei Medical Science Research Program, No: 20221695.

Author information

Authors and Affiliations

  1. Department of Urology, Shijiazhuang People’s Hospital, 9 Fangbei Road, Shijiazhuang, 050011, Hebei Province, China

    Chao Li, Yongqiang Xiao, Heran Cao, Yan Chen, Shen Li & Fengchao Yin

Authors
  1. Chao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yongqiang Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heran Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fengchao Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

FY designed and conducted the study. HC, YC, and SL analyzed the data. CL, FY, and YX wrote and revised the manuscript. FY had read and approved the manuscript before its submission.

Corresponding author

Correspondence to Fengchao Yin.

Ethics declarations

Ethical Approval

All data in this study are open source and do not require ethics committee review.

Consent for Publication

Not applicable.

Competing Interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (RAR 1925 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, C., Xiao, Y., Cao, H. et al. Cuproptosis Regulates Microenvironment and Affects Prognosis in Prostate Cancer. Biol Trace Elem Res 202, 99–110 (2024). https://doi.org/10.1007/s12011-023-03668-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12011-023-03668-2

Keywords

Search

Navigation